The therapy was also associated with reduced urinary calcium excretion and stable serum calcium concentration in patients with hypoparathyroidism.
PTH (1-84) for 7 years is linked to reduced calcium and calcitriol supplementation.
Shire announced the launch of Natpara (parathyroid hormone) for injection indicated as adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism
The FDA has approved Natpara (parathyroid hormone) to control hypocalcemia in patients with hypoparathyroidism.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted to recommend approval of recombinant human parathyroid hormone for hypoparathyroidism.
Patients with hypoparathyroidism may benefit from treatment with recombinant human parathyroid hormone.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Adjunctive Aripiprazole Lowers Prolactin Levels in Women With Psychosis
- When Physicians Become Patients: Challenges in Seeking Health Care
- Statin Use and Cardiovascular Risk Perception Varies Among Races
- Impact of a Longer Work Week on Diabetes Incidence
- Relationship Between Estradiol Level and Mortality in Elderly Men